☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
TOURMALINE-MM2
Takeda Reports Results of Ninlaro (ixazomib) in P-III TOURMALINE-MM2 Study for Transplant Ineligible Patients with Multiple Myelom...
March 11, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.